Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, et al. Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2021;56:1964-1970.
PMID: 33824442